Retracted: Maternal traditional Chinese medicine exposure and risk of congenital malformations: a multicenter prospective cohort study
Acta Obstetricia et Gynecologica Scandinavica · 2023
DOI: 10.1111/aogs.14553 ↗At a glance
Multizentrische Studie in Acta Obstetricia et Gynecologica Scandinavica, 2023. Written by Ting Peng and 10 co-authors. Institution: Department of Obstetrics, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Heart Defects, Congenital, Pregnancy Complications, Abnormalities, Drug-Induced, Congenital Abnormalities. Cited 8 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China.
Abstract (original language)
Introduction
The potential teratogenic risk of traditional Chinese medicine (TCM) is of widespread concern; however, related evidence is largely absent in humans. This study aimed to compare the prevalence of congenital malformations between pregnant women with and without TCM exposure. Material and methods This was a multicenter prospective cohort study of 17 713 women who participated in a survey on periconceptional TCM exposure. Primary outcome was congenital malformations diagnosed from a survey conducted on the day 42 after delivery.
Results
A total of 16 751 pregnant women with 273 congenital malformations were included in the analysis. Fetuses exposed to TCM had an increased risk of congenital malformations compared to those without exposure (odds ratio [OR] 2.10; 95% confidence interval [CI] 1.09–4.02) after controlling for potential confounders. There were significant associations with congenital malformations in women with early pregnant exposure (OR 2.04, 95% CI 1.00–4.20) and for those who received ≥2 TCM formulas (OR 5.84, 95% CI 1.44–23.65). Pre‐pregnancy TCM exposure was significantly associated with an increased risk of congenital heart defects (OR 12.69; 95% CI 3.01–53.51).
Conclusions
Periconceptional TCM exposure is associated with an increased risk of congenital malformation. This effect was cumulative and sensitive to periconceptional age. Therefore, TCM deserves more attention and should be used cautiously for pregnant women and those trying to become pregnant.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Obstetrics, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
- Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Shanghai, China.
- Center for Medical Ultrasound, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
- Medical Center of Diagnosis and Treatment for Cervical Disease, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
- Department of Clinical Epidemiology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
ORCID profiles: Jiang-Nan Wu
Funding
- National Natural Science Foundation of China
Cite
APA
Peng, T., Yin, L. L., Xiong, Y., Xie, F., Ji, C. Y., Yang, Z., Pan, Q., Li, M. Q., Deng, X. D., Dong, J., & Wu, J. N. (2023). Retracted: Maternal traditional Chinese medicine exposure and risk of congenital malformations: a multicenter prospective cohort study. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.14553
Vancouver
Peng T, Yin LL, Xiong Y, Xie F, Ji CY, Yang Z, et al. Retracted: Maternal traditional Chinese medicine exposure and risk of congenital malformations: a multicenter prospective cohort study. Acta Obstetricia et Gynecologica Scandinavica. 2023. doi:10.1111/aogs.14553
BibTeX
@article{Peng2023,
author = {Peng, Ting and Yin, Lin-Liang and Xiong, Yu and Xie, Feng and Ji, Chun-Ya and Yang, Zhong and Pan, Qi and Li, Ming-Qing and Deng, Xue-Dong and Dong, Jing and Wu, Jiang-Nan},
title = {Retracted: Maternal traditional Chinese medicine exposure and risk of congenital malformations: a multicenter prospective cohort study},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2023},
doi = {10.1111/aogs.14553}
}
EUVIMED